LMNB1 and breast cancer: Detecting TIS based on a three-marker signature involving the downregulation of lamin B1 and Ki-67, as well as the upregulation of p16INK4a revealed that 31% of breast cancer samples exhibited a shift toward a TIS-positive phenotype after exposure to neoadjuvant chemotherapy (130).